Aratana's stock falls after newest pet drug treatment fails study
Aratana Therapeutics Inc.'s newest treatment for dogs failed an effectiveness study, the Leawood animal health company announced Friday.
Its latest drug candidate, a fat-derived stem cell treatment, was intended to treat dogs with advanced osteoarthritis. The treatment, dubbed AT-016, had entered pivotal trials, meaning the data would be used as evidence for approval by the Food and Drug Administration.
However, Aratana (Nasdaq: P ETX) did not meet the criteria to demonstrate efficacy, and between…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Elise Reuter Source Type: news
More News: American Health | Food and Drug Administration (FDA) | Health Management | Osteoarthritis | Stem Cell Therapy | Stem Cells | Study